GATOR1 Complex Biology, Epilepsy Genetics, and High-Purity Reagents for mTORC1 Pathway Modulation
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NPRL3 and GATOR1 complex drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NPRL3 Full-Length Recombinant Protein. High purity (>95%), Sequence Verified, HEK293 Expressed (Native folding). Endotoxin <1EU/ug. Theoretical MW confirmed by SDS-PAGE. | View NPRL3 Products |
| Mutant Antigen | NPRL3 Epilepsy-Associated Mutants (R403Q, G420R). Sequence Verified by Mass Spec; Available as matched WT/Mutant pairs for functional comparison. | View NPRL3 Products |
| Gene Delivery | NPRL3 Promise-ORF / Lentivirus. Full-length ORF with N-terminal FLAG or Myc tags; also available as shRNA/CRISPR vectors for stable cell line construction and disease modeling. | View NPRL3 Products |
| Validator | NPRL3 siRNA Set (3 unique sequences). For knockdown verification and specificity controls in autophagy flux assays and GATOR1-deficiency modeling. | View NPRL3 Products |
| Complex Partner | NPRL2 Recombinant Protein. Forms obligate heterodimer with NPRL3; Essential for functional GATOR1 assembly. >95% purity. | View NPRL2 Products |
| Complex Partner | DEPDC5 Recombinant Protein. Scaffold component of GATOR1; Critical for Rag GTPase recruitment. HEK293 expressed. | View DEPDC5 Products |
| Downstream Target | RagA (RRAGA) Recombinant Protein. GTPase substrate of GATOR1; Required for GAP activity assays. High purity. | View RRAGA Products |
| Related Target | MTOR. Downstream kinase hyperactivated in NPRL3-loss disease models; key readout for pathway modulation studies. | View MTOR Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trimeric Complex Assembly (NPRL3-NPRL2-DEPDC5) | Individual components >95% purity; Co-incubation validated; Low endotoxin preserves protein-protein interaction activity |
| Epilepsy Variant Functional Validation | Disease-mutant proteins (R403Q, G420R) available with sequence-verified WT controls; Suitable for SPR and ITC |
| Intracellular Target Delivery Studies | Lentivirus Premade Particles for stable NPRL3-overexpressing lines; Endotoxin controlled (<1EU/ug DNA) |
| GATOR1 vs GATOR2 Selectivity | Counter-screening proteins available: SZT2, ITFG2, KPTN for specificity profiling |
| Disease-Model Generation | Lentiviral CRISPR/shRNA vectors to create NPRL3 knockout cell lines for mTOR inhibitor screening and phenotypic rescue assays |
| Orthogonal Validation | High-purity recombinant protein and matched siRNA sets enable knockdown/rescue specificity controls for target engagement studies |
Live NPRL3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Epilepsy Genetics Research
- mTORC1 Pathway Mechanism Studies
- Recent Patent Filings (GATOR1 Complex)
Global Clinical Landscape & Future Outlook
The NPRL3 target represents an emerging frontier in precision neurology and cancer metabolism. As a core component of the GATOR1 complex (with NPRL2 and DEPDC5), NPRL3 loss-of-function mutations cause familial focal epilepsy with variable foci (FFEVF) and malformations of cortical development (MCD), driving interest in gene replacement and small-molecule stabilizers. Concurrently, oncology researchers are exploring GATOR1 activation as a means to suppress hyperactive mTORC1 signaling in solid tumors resistant to first-generation mTOR inhibitors (e.g., rapamycin analogs). Current development is predominantly preclinical, focusing on understanding the trimeric NPRL3-NPRL2-DEPDC5 interface structure to enable protein-protein interaction (PPI) modulation. The next wave of R&D is targeting allosteric activators of GATOR1 GAP activity, molecular glues that stabilize the functional complex, and gene therapy strategies to restore NPRL3 expression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Modulators | Academic Consortia, Early Biotech | Familial Focal Epilepsy, mTOR-opathies | Trimeric Complex Formation Assay (Need pure NPRL3+NPRL2+DEPDC5 proteins) |
| Small Molecule mTOR Inhibitors (Repurposing) | Novartis, Pfizer | Focal Epilepsy, Cortical Dysplasia | Cell-based Screening (Need lentivirus to build NPRL3-KO models) |
| Gene Replacement Therapy (AAV) | Neurology-Focused Gene Therapy Biotechs | FFEVF (Loss-of-function mutations), Drug-Resistant Epilepsy | Functional Protein Expression (WT vs Mutant comparison assays; need high-purity protein and ORF vectors) |
| Targeted Protein Degradation (PROTAC) | Preclinical Exploratory Labs | Oncology (solid tumors) | Cellular Overexpression Lines (Need NPRL3 lentivirus ORF for overexpression) |
| Intracellular Biologics (Peptide-based) | Emerging (Peptide-based Platforms) | Refractory Epilepsy | Cell Permeability & Stability (Need high-concentration protein stocks) |